Skip to main content
Nanjing Leads Biolabs Co., Ltd. logo

Nanjing Leads Biolabs Co., Ltd. — Investor Relations & Filings

Ticker · 9887 ISIN · CNE1000070H8 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 90 across all filing types
Latest filing 2026-05-20 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 9887

About Nanjing Leads Biolabs Co., Ltd.

https://www.leadsbiolabs.com

Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company engaged in the integrated discovery, development, and commercialization of innovative antibody-based therapeutics. The company's core focus is on addressing global unmet patient needs across major therapeutic areas, including oncology, autoimmune diseases, and critical illnesses. Utilizing an in-house R&D platform, Leads Biolabs develops novel candidate drugs. Key pipeline assets include bifunctional inhibitors, such as DNTH-212, which targets BDCA2 and BAFF/APRIL for the treatment of autoimmune conditions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE H SHARE AWARD SCHEME
Transaction in Own Shares Classification · 90% confidence The document is a voluntary announcement by Nanjing Leads Biolabs regarding the instruction to the trustee to acquire existing H Shares on-market under the H Share Award Scheme. It describes a share repurchase arrangement (acquisition of own shares) rather than the issuance of new shares or financing. This fits the definition of "Transaction in Own Shares" (POS), which covers share buybacks or repurchases. There is no substantive financial statements or voting information; it’s a specific share transaction announcement.
2026-05-20 English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) APPROVED BY CDE
Regulatory Filings
2026-05-19 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 91% confidence The document is the full “Articles of Association” of Nanjing Leads Biolabs Co., Ltd., containing detailed corporate governance rules, shareholder rights, board and management structure, voting procedures, and other internal governance provisions. It is not an earnings release, financial report, or announcement of another report, but rather the company’s definitive governance charter. Under the defined categories, this aligns precisely with a Governance Information filing (CGR).
2026-05-15 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the poll results of the 2026 Annual General Meeting, detailing vote counts for ordinary and special resolutions, including the appointment of a non-executive director and amendments to the articles of association. It does not contain the AGM materials themselves nor detailed financial statements. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-15 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 88% confidence The document is a formal announcement listing the company’s board members by category (executive, non-executive, independent) and detailing committee memberships (Audit, Nomination, Remuneration). It does not contain financial data or voting results, nor is it a call transcript or earnings release. It is focused on the company’s board structure and governance arrangement rather than reporting a change or election outcome. This aligns with Governance Information (CGR): detailing the company’s board structure and governance practices.
2026-05-15 English
INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement by Nanjing Leads Biolabs regarding Stock Exchange approval for the conversion of unlisted shares into H shares and details of the resulting shareholding structure. This is an announcement of a capital structure change (issuance/listing of new shares) rather than a financial report, management change, or earnings release. According to the filing taxonomy, such share conversion and listing notices fall under Share Issue/Capital Change (Code: SHA).
2026-05-14 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.